In Reply We thank DeMasi, as well as van de Gronde and Pieters, for their interest in our article1 estimating the research and development (R&D) spending to bring a single cancer drug to the US market and its revenue postapproval.
First, both DeMasi and van de Gronde and Pieters raise the question of whether our analysis includes companies who were more successful than average, which would lead us to underestimate R&D spending.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Prasad V, Mailankody S. Assessing Pharmaceutical Research and Development Costs—Reply. JAMA Intern Med. 2018;178(4):588–589. doi:10.1001/jamainternmed.2017.8737
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: